HLB bioStep Co.,Ltd. (KOSDAQ:278650)
South Korea · Delayed Price · Currency is KRW 2,395.00
+155.00 (6.92%)
At close: Aug 11, 2026
HLB bioStep Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 73,958 | 74,050 | 58,169 | 52,814 | 86,277 | 64,403 |
Revenue Growth | 22.89% | 27.30% | 10.14% | -38.78% | 33.96% | 10.05% |
Gross Profit Gross Profit Growth | 55,323 | 55,907 | 40,830 | 35,281 | 53,934 | 41,256 |
Operating Income Operating Income Growth | -8,701 | -8,639 | -13,048 | -1,186 | 5,309 | 9,007 |
Net Income Net Income Growth | -19,277 | -18,962 | -8,564 | -164.04 | -1,008 | 11,031 |
Earnings Per Share EPS Growth | -1085.34 | -1121.56 | -510.23 | -10.69 | -72.00 | 790.00 |
EPS Growth | - | - | - | - | - | 31.42% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Pet Medical Sector Pet Medical Sector Growth | 13,217 | 13,001 | 12,028 | 11,109 | 30,344 | 19,763 |
Ministry of Bioinfrastructure Ministry of Bioinfrastructure Growth | 37,218 | 37,857 | 29,942 | 21,667 | 23,762 | 14,006 |
Non-Clinical CRO Sector Non-Clinical CRO Sector Growth | 23,522 | 23,192 | 16,199 | 20,038 | 32,171 | 30,634 |
Total Total Growth | 73,958 | 74,050 | 58,169 | 52,814 | 86,277 | 64,403 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 30,792 | 43,343 | 46,861 | 70,377 | 97,064 | 10,393 |
Total Debt Total Debt Growth | 30,960 | 30,765 | 34,696 | 60,637 | 91,641 | 16,304 |
Net Cash (Debt) Net Cash Growth | -168.07 | 12,578 | 12,165 | 9,740 | 5,424 | -5,911 |
Net Cash Growth | - | 3.40% | 24.90% | 79.57% | - | - |
Net Cash Per Share Net Cash Per Share Growth | -9.46 | 743.97 | 724.71 | 634.81 | 387.40 | -422.29 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -2,360 | 3,086 | -11,670 | 5,192 | 6,481 | 8,463 |
Capital Expenditures CapEx Growth | -1,939 | -1,973 | -8,924 | -4,002 | -4,894 | -19,598 |
Free Cash Flow Free Cash Flow Growth | -4,299 | 1,113 | -20,594 | 1,189 | 1,587 | -11,135 |
Free Cash Flow Growth | - | - | - | -25.03% | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 74.80% | 75.50% | 70.19% | 66.80% | 62.51% | 64.06% |
Operating Margin | -11.77% | -11.67% | -22.43% | -2.25% | 6.15% | 13.98% |
Pretax Margin | -24.51% | -23.67% | -19.82% | 0.62% | -2.72% | 19.92% |
Profit Margin | -26.06% | -25.61% | -14.72% | -0.31% | -1.17% | 17.13% |
FCF Margin | -5.81% | 1.50% | -35.40% | 2.25% | 1.84% | -17.29% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | - | 19.87 |
P/FCF Ratio | - | 110.34 | - | 204.19 | 206.70 | - |
PS Ratio | 0.56 | 1.66 | 3.03 | 4.60 | 3.80 | 3.40 |